These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 31551181)

  • 1. Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases.
    Li Z; Tu Y; Wu Q; Wang Z; Li J; Zhang Y; Sun S
    Clin Breast Cancer; 2020 Apr; 20(2):e151-e163. PubMed ID: 31551181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
    Zhao H
    Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
    Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
    Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
    Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
    Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study.
    Ethier JL; Ocaña A; Rodríguez Lescure A; Ruíz A; Alba E; Calvo L; Ruíz-Borrego M; Santaballa A; Rodríguez CA; Crespo C; Ramos M; Gracia Marco J; Lluch A; Álvarez I; Casas M; Sánchez-Aragó M; Carrasco E; Caballero R; Amir E; Martin M
    Eur J Cancer; 2018 May; 94():199-205. PubMed ID: 29573665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
    Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
    JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
    BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of adjuvant chemotherapy in patients with ER + /HER2- breast cancer, assessed by propensity score matching: significance of nuclear grade and nodal status.
    Tanaka N; Hirano A; Hattori A; Ogura K; Kamimura M; Inoue H; Yukawa H; Sakaguchi S; Matsuoka A; Kodera A; Shimizu T
    Breast Cancer; 2021 Jan; 28(1):40-47. PubMed ID: 32592141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients.
    Kimbung S; Inasu M; Stålhammar T; Nodin B; Elebro K; Tryggvadottir H; Ygland Rödström M; Jirström K; Isaksson K; Jernström H; Borgquist S
    Breast Cancer Res; 2020 Nov; 22(1):123. PubMed ID: 33176848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological Characteristics and Long-term Outcomes in Node-negative Breast Cancer.
    Agostinetto E; Giordano L; Torrisi R; De Sanctis R; Masci G; Losurdo A; Zuradelli M; Tinterri C; Gatzemeier W; Testori A; Alloisio M; De Rose F; Fernandes B; Santoro A
    Clin Breast Cancer; 2020 Aug; 20(4):e481-e489. PubMed ID: 32279915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
    Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
    Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
    Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H
    PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study.
    Wei JL; Zhang JX; Fu DY
    World J Surg Oncol; 2018 Dec; 16(1):236. PubMed ID: 30558615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients.
    Cantini L; Pistelli M; Merloni F; Fontana A; Bertolini I; De Angelis C; Bastianelli L; Della Mora A; Santinelli A; Savini A; Maccaroni E; Diodati L; Falcone A; Berardi R
    Clin Breast Cancer; 2020 Feb; 20(1):e89-e98. PubMed ID: 31378534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.
    Yu KD; Jiang YZ; Hao S; Shao ZM
    BMC Med; 2015 Oct; 13():254. PubMed ID: 26437901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database.
    Hwang KT; Kim J; Jung J; Chang JH; Chai YJ; Oh SW; Oh S; Kim YA; Park SB; Hwang KR
    Clin Cancer Res; 2019 Mar; 25(6):1970-1979. PubMed ID: 30559169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.
    Yu KD; Di GH; Wu J; Lu JS; Shen KW; Liu GY; Shen ZZ; Shao ZM
    J Cancer Res Clin Oncol; 2008 Dec; 134(12):1347-54. PubMed ID: 18488249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of triple negative phenotype on breast cancer prognosis.
    Kaplan HG; Malmgren JA
    Breast J; 2008; 14(5):456-63. PubMed ID: 18657139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
    Liu D; Zhou K
    Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.